Author | Cheryl Guttman Krader, BS, Pharm


Overactive bladder treatment maintains favorable long-term safety profile

August 21, 2020

Beta 3-adrenergic receptor agonist’s benefits observed at 52 weeks, investigators report.

PET imaging agent found superior to CT for lymph node staging in prostate cancer

August 13, 2020

Agent shows statistically significant superiority to conventional computed tomography.

Men on active surveillance for prostate cancer may benefit from Mediterranean diet

July 28, 2020

Mediterranean diet score was modestly associated with time to grade group progression.

Study reveals risk factors for upgrading in active surveillance for prostate cancer

July 27, 2020

“Our findings suggest that genomic score and PSA density are risk factors for upgrading within 3 years of commencing active surveillance,” the investigators wrote.